论文部分内容阅读
对采用 Norplant R埋植剂和仿制 Norplant的国产埋植剂 型避孕的育龄妇女骨密度和骨代谢改变进行了 1年的随机前瞻性临床观察。 6 1例正常妇女被分为两组 :Norplant埋植剂组 30例 ,国产埋植剂组 31例。两组于埋植前和埋植后第 12个月时采用双能 X线骨密度测定仪 (DEXA)分别测定了腰椎 L2 ～ L4、股骨近端骨密度和骨矿含量。两组妇女埋植后第 12个月时腰椎 L2 ～ L4骨密度和骨矿含量均较埋植前明显增加 (P<0 .0 1) ,Norplant组骨密度平均增加2 .40 % ,骨矿含量平均增加 3.34 % ,国产埋植剂组分别增加 2 .75 %和 4.47% ;从年龄分析 ,以 2 5～ 2 9岁组腰椎 L2 ～ L4骨密度埋植后增加最为显著 ,Norplant组 P<0 .0 5 ,国产埋植剂组 P<0 .0 1。国产埋植剂组妇女埋植后第 12个月时股骨大粗隆骨密度和骨矿含量较埋植前明显增加 (P<0 .0 1) ;国产埋植剂组妇女空腹尿羟脯氨酸 /肌酐比值埋植后第 12个月时较埋植前明显下降 (P<0 .0 1) ;对使用妇女腰椎、股骨骨密度和骨代谢生化指标的影响 ,在两种埋植剂之间埋植前后比较均无显著差别 (P>0 .0 5 )。左旋 - 18甲基炔诺酮皮埋避孕剂对绝经妇女的骨骼是非有害的 ,对年轻妇女骨峰值的获得无明显影响。
A year-long prospective randomized clinical trial was conducted on changes in bone mineral density and bone metabolism in women of childbearing age with contraceptive implantations of Norplant R and Norplant. Sixteen normal women were divided into two groups: 30 in Norplant implants and 31 in Chinese implants. The lumbar L2 ~ L4, proximal femur BMD and bone mineral content were measured by DEXA before implantation and 12 months after implantation. At 12 months after implantation, the BMD and bone mineral density of L2 ~ L4 in lumbar spine increased significantly (P <0. 01) and the average density of bone in Norplant group increased 2.40% Content increased 3.34% on average, the native implants increased 2.75% and 4.47%, respectively. From the age analysis, the lumbar L2 ~ L4 BMD in 25 ~ 29 years old group increased most significantly after implantation, norplant group P < 0 .0 5, domestic implants group P <0. The bone mineral density and bone mineral content of femoral greater trochanter increased significantly (P <0.01) on the 12th month after implants in Chinese implants group. In the implants, the urinary hydroxyproline Acid / creatinine ratio at 12 months after transplantation significantly decreased compared with that before implantation (P <0.01); on the use of women’s lumbar, femoral bone mineral density and biochemical markers of bone metabolism in two implants There was no significant difference between before and after implantation (P> 0.05). L-18 Norfromone Skin Impregnation Agent is non-harmful to the bones of postmenopausal women and has no significant effect on bone gain in young women.